UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST BOARD OF DIRECTORS THURSDAY 24 JUNE 2010

Title:	PERFORMANCE INDICATORS REPORT & REVIEW OF KEY PERFORMANCE INDICATORS FOR 2010/11							
Responsible Director:	Executive Director of Delivery							
Contact:	Andy Walker, Divisional Planning Manager Daniel Ray, Director of Informatics & Patient Administration							

Purpose:	To update the Board of Directors of the Trust's performance against key indicators, including Care Quality Commission (CQC) targets, risk ratings against standards included in the Monitor Compliance framework, and performance against internal targets.					
Confidentiality Level & Reason:	N/A					
Medium Term Plan Ref:	Affects all strategic aims.					
Key Issues Summary:	 The following indicators are currently not in line with targets and therefore exception reports have been provided: A&E 4 hour waits <i>C. difficile</i> Quality of Stroke Care Delayed Transfers of Care 62 day GP referral to treatment 62 day referral from screening to treatment Short term sickness Electronic Patient Survey response rate Omitted non-antibiotic doses Readmission & non-emergency mortality audits response rates 					
Recommendations:	The Board of Directors is requested to: Accept the report on progress made towards achieving performance targets and associated actions.					
Signed:	Date: 11 June 2010					

UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST BOARD OF DIRECTORS THURSDAY 24 JUNE 2010

PERFORMANCE INDICATORS REPORT & REVIEW OF KEY PERFORMANCE INDICATORS FOR 2010/11

PRESENTED BY THE EXECUTIVE DIRECTOR OF DELIVERY

1. **Purpose**

This paper provides the Board of Directors with an update on the Trust's performance against key indicators, including Care Quality Commission (CQC) targets, risk ratings against standards included in the Monitor Compliance framework and internal targets. Performance against these indicators is shown in Appendix A.

2. **Exception reports**

Exception reports where monthly data are available are contained in Appendix B. A&E 4 hour waits and stroke length of stay were below target and delayed transfers of care and the number of post 48 hour C. difficile cases exceeded the threshold in May therefore these indicators are included. A report on the cancer targets is included as the 62 day GP referral and 62 day referral from screening targets were below target for April.

The exception report this month only contains reports on those internal indicators that are red. Agency spend is not included as accounts are not produced for month 1 therefore the data for this indicator is not available. Cancellation of follow-up outpatient appointments was amber in May therefore this indicator has returned to quarterly exception reporting.

The following internal targets are currently red:

- a) Short term sickness
- b) Electronic Patient Survey response rate
- c) Omitted non-antibiotic doses
- d) Readmission & non-emergency mortality audits response rates

3. **Recommendations**

The Board of Directors is requested to:

Accept the report on progress made towards achieving performance targets and associated actions.

Tim Jones Executive Director of Delivery

p level grouping		2nd level grouping	KPI	Weighting	
tional Performance	Amber	Monitor targets	MRSA	· ·	
			C. difficile	1	
			Cancer		
			31 days first	0.5	5
			Cancer		
			31 days subs - drugs		1
			Cancer 31 days subs - surgery		
			Cancer 31 days subs -		
			radiotherapy	ŕ	
			Cancer		
			62 days - GP referral		
			Cancer 62 days - screening		
			Cancer		
			2 wks	0.5	-
				0.0)
			Breast		_
			2 wks	0.8	5
			18 wks - admitted	ŕ	
			18 wks - non-admitted		l
			A&E 4 hr waits	0.5	
			MRSA screening	0.5	
			Learning Disabilities	0.0	
				0.8	,
		Existing Commitments	Patient ethnic group recorded	· ·	I
		Latering Committee	Delayed transfers of care		
			A&E 4 hr waits		
			RACPC 2 wk waits		
			Cancelled operations	ŕ	
			Primary PCI	· ·	
		National Priorities	Engagem't in Clinical Audit		I
		Hadonal Hondes	Heart disease audits		
			Stroke		
			care	· ·	
			MRSA	ŕ	
			C. difficile		
			18 wks	·	
			Cancer 31 days		
			Cancer 62 days		
			2 wks - cancer & breast	·	
			Patient experience	·	
			Staff satisfaction	· ·	
			Learning Disabilities		Nev
				-	
		Core Standards			Nev
					Nev
					Nev
					New
				<mark>6</mark>	New
				<mark>7</mark> ·	New
					New
					New
					Nev
					New
					New
			1	<mark>3</mark>	New
					New
					New
					New

		Responsiveness to patient needs
Patient Care	Experience	CQUIN
		Complaint response
		Cancelled appts - new Cancelled appts - F/up
		Slot availability
		Electronic patient survey
		response rate
	Safety	Incidents
		Never events
		VTE risk assess't CQUIN
		Falls assess't CQUIN Antibiotic prescription to admin
		delays CQUIN
		Omitted drugs
		SMR
	Outcomes	(103.97)
		CVC infection CQUIN
		Pressure ulcer CQUIN
		Readmission audit response rate
		Non-emergency mortality audit
		response rate
Workforce	Resources	Sickness - short term
		Sickness - long term
		Internal Agency rate
		External Agency rate Vacancy rate
	Capability	PDRS
		Mandatory training
		Corporate induction
		Local induction
Efficiency	Innovation	
Efficiency	Innovation	Electronic obs chart CQUIN Research income (commercial)
Efficiency	Innovation	Research income (commercial)
Efficiency	Innovation	
Efficiency	Innovation	Research income (commercial) Research income (non- commercial) Studies/trials in progress
Efficiency	Innovation	Research income (commercial) Research income (non- commercial) Studies/trials in progress Patient accruals
Efficiency	Innovation	Research income (commercial) Research income (non- commercial) Studies/trials in progress
Efficiency		Research income (commercial) Research income (non- commercial) Studies/trials in progress Patient accruals Research publications
Efficiency	Innovation	Research income (commercial) Research income (non- commercial) Studies/trials in progress Patient accruals Research publications DNAs - new
Efficiency		Research income (commercial) Research income (non- commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up
Efficiency		Research income (commercial) Research income (non- commercial) Studies/trials in progress Patient accruals Research publications DNAs - new
Efficiency		Research income (commercial) Research income (non- commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation
Efficiency		Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre resesion utilisation Daycase rate
Efficiency		Research income (commercial) Research income (non- commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation
	Process	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation Daycase rate LOS to meet bedholding
Efficiency Governance		Research income (commercial) Research income (non- commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation Daycase rate LOS to meet bedholding Health and safety
	Process	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers
	Process	Research income (commercial) Research income (non- commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation Daycase rate LOS to meet bedholding Health and safety
	Process	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 2
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 3
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 2 Clinical Quality 3 Clinical Quality 4
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 2 Clinical Quality 4 Patient Experience 1
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 3 Clinical Quality 4 Patient Experience 1 Patient Experience 1
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - rew Do fletters - dictation to post Theatre isstion utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 2 Clinical Quality 3
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 3 Clinical Quality 4 Patient Experience 1 Patient Experience 2 Patient Experience 3 Patient Experience 3 Patient Experience 4
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - rew Do fletters - dictation to post Theatre isstion utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 2 Clinical Quality 3
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 2 Clinical Quality 4 Patient Experience 1 Patient Experience 3 Patient Experience 4 Education & Training 1
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 3 Clinical Quality 4 Patient Experience 1 Patient Experience 3 Patient Experience 4 Education & Training 1 Education & Training 3 Education & Training 4
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre ist utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 2 Clinical Quality 4 Patient Experience 1 Patient Experience 3 Patient Experience 4 Education & Training 1 Education & Training 2 Education & Training 4
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre list utilisation Theatre session utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 2 Clinical Quality 4 Patient Experience 1 Patient Experience 2 Patient Experience 4 Education & Training 1 Education & Training 2 Education & Training 3 Education & Training 4 Research & Innovation 1 Research & Innovation 2
	Process Clinical & Corporate Governance	Research income (commercial) Research income (non-commercial) Studies/trials in progress Patient accruals Research publications DNAs - new DNAs - F/up OP letters - dictation to post Theatre ist utilisation Daycase rate LOS to meet bedholding Health and safety Risk registers National Clinical Audits Clinical Quality 1 Clinical Quality 2 Clinical Quality 4 Patient Experience 1 Patient Experience 3 Patient Experience 4 Education & Training 1 Education & Training 2 Education & Training 4

Last updated		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
20/07/2000		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		
29/07/2009		

29/07/2009

29/07/2009


29/07/2009

29/07/2009 29/07/2009 29/07/2009 29/07/2009 29/07/2009

29/07/2009 29/07/2009 29/07/2009


2010/11 Key Performance Indicator Report

Where data is not currently available indicators have been assigned 'amber' unless considered high risk where they have been assigned 'red'.




20 May 2010





Exception Report for 24 June 2010 Board of Directors' Performance Report




APPENDIX B

C. difficil	e - Post	48 hour d	cases			Monitor	& CQC	National	Priorities	8	> 193	≤ 193	≤ 164
	Apr 10	May 10	Jun 10	Jul 10	Aug 10	Sep 10	Oct 10	Nov 10	Dec 10	Jan 11	Feb 11	Mar 11	YTD
C. difficile	18	18											36
There were 18 post 48 hour <i>C. diff</i> cases in May which is above the trajectory of 13.66 to meet the full year trajectory of 164. Please refer to Chief Nurse's Infection Control Report for further details and action taken.										Oct 09 Nov 09	Dec (09 Jan 10	Feb 10 Mar 10 Arr 10	May 10
A&E 4 ho	our waits				Мс	onitor &	CQC Ex	isting Co	ommitme	nts	< 97%	97-98%	≥ 98%
	Apr 10	May 10	Jun 10	Jul 10	Aug 10	Sep 10	Oct 10	Nov 10	Dec 10	Jan 11	Feb 11	Mar 11	YTD
4 hr waits	98.02%	97.24%											97.61%
at 97.24%. However wh for the year the capacity discharges. details of act The Governr to 95% for	Following performance of 98.02% in April, performance in May was below targe at 97.24%. Year to date performance is therefore below target at 97.61% However when Katie Road walk-in centre performance is included performance or the year stands at 98.44%. Performance has been siginifcantly affected by the capacity problems at Selly Oak caused by the large number of delayed discharges. Please see the Delayed Transfers of Care exception report for details of action taken in response to these problems. The Government has indicated that the threshold for this target is to be reduced o 95% for 2010/11 therefore it is likely that when the revised Operating Framework is published this level of performance will result in the target being								Oct 08 Nov 08 Dec 08 Jan 09	Feb 09 Mar 09 Apr 09 May 09	Jun 09 Jul 09 Sep 09 Set 09 Oct 00	Nov 08 Dec 09 Jan 10 Feb 10	Mar 10 Apr 10 May 10


Quality of	f Stroke	Care					CQC N	ational P	riorities	Thresholds not available			
	Apr 10	May 10	Jun 10	Jul 10	Aug 10	Sep 10	Oct 10	Nov 10	Dec 10	Jan 11	Feb 11	Mar 11	YTD
Stroke	50.0%	47.1%											41.8%
The percenta on a stroke percentage for Moseley Hall agreed contri improve whe difficult to pro- steps to en- exhausted to admitted follo Performance week in May to the unit du is also likely to	unit in May or April admi Hospital ler ractually wit n it is include otect the stru- sure that the ensure that the wing a strok was also a due to an ou ring this peri	y 2010 was ssions has in ogth of stay w h NHS Sou ed. The capa oke admission ese are on , as far as por e. ffected by the utbreak of no od will be dis	47.1%. Fo ncreased to which is only uth Birming acity problem on beds on ally used wh ossible, the he closure of rovirus. Son	llowing addi 50%. These v available o nam but th ns seen at S the unit but nen all othe unit is alway of stroke un ne patients r	itional disch figures do r n a quarterl e percentag elly Oak hav t Division 3 er capacity s able to tak it to admiss not able to be	arges the not include y basis as ge should ve made it has taken has been ke patients ions for a e admitted	100% 90% - 80% - 70% - 60% - 50% - 40% - 30% - 20% - 10% - 0% -	Q2 08/09	Q3 08/09 Q4 08/09	Q1 08/1/0	d2 09/10 G3 09/10	Q4 09/10 Apr 10	May 10

Delayed Transfers of Care									sting Comr	nitments	> 4.0%	≤ 4.0%	≤ 3.5%
	Apr 10 May 10 Jun 10 Jul 10 Aug 10 Sep 10 Oct 10							Nov 10	Dec 10	Jan 11	Feb 11	Mar 11	YTD
DToC	3.8%												3.8%

Delayed transfers of care rose to 3.76% in April from 3.49% in March against a 5.0% target of 3.5%. There were 187 delays over the month. The current financial climate 4.5% has led to Birmingham City Council cutting back on agency and overtime for social 4.0% workers. This has resulted in severe delays in Social Services arranging care packages for patients who are ready for discharge. In some cases there has been a 3.5% delay of 18 days between social services being told that a package needs to be 3.0% arranged and a social worker being assigned to the case. The problems have been 2.5% compounded further by the closure of 30 community hospital beds in early May by 2.0% South Birmingham Community Health. In the first 8 weeks of the financial year there 1.5% have been 340 delayed discharges compared to 311 in 2009/10. Additional capacity has been opened at both SOH and QEH to compensate for that 1.0% lost due to beds being occupied by patients with delayed discharges. Daily 0.5% teleconferences are being held with NHS South Birmingham and the problems with 0.0% social services have been escalated within Birmingham City Council. Additional social workers were put in place over the weekend of 22-23 May to arrange packages of care. South Birmingham Community Health is to open an additional 10 beds for patients for those requiring NHS funded continuing care. The Discharge Team is reviewing all medical patients to identify whether there are any blockages to discharge that can be readily resolved (e.g. provision of equipment).



Sickness rate - short term > 2.2% 2.0-2.2% ≤ 2.0% Workforce - Resources Sickness rate - long term > 2.6% 2.3-2.6% ≤ 2.3% Apr 10 May 10 Jun 10 Jul 10 Aug 10 Sep 10 Oct 10 Nov 10 Dec 10 Jan 11 Feb 11 Mar 11 YTD ST sickness 2.30% 2.30% LT sickness 2.00% 2.00% For the month of April 2010 the Trust sickness absence rate was 4.30%; a 5.0% fall from 4.65% in March. Short term absence fell from 2.80% from 2.30% 4.5% and long term absence rose from 1.85% to 2.00%. 4.0% The hotspot areas are: Unregistered nursing, West 2, West 3, A5, C3, D4, 3.5% S8, Edgbaston, Phlebotomy and Cardiac Theatres. Reasons include D&V 3.0% post-surgery recovery, stress and musculoskeletal issues. The action plan 2.5% 2.0% to tackle sickness has been in place since February and appears to have 1.5% had an impact on the absence rates. It is envisaged that after the move to 1.0% QEHB some current hotspots may increase whilst others decrease; these 0.5% areas will be closely monitored. 0.0% Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr



ST eicknose

APPENDIX B

Omitted of	drugs - A	ntibiotic	S			De	tiont Cof	ot i	> 10%	5-10%	≤ 5%		
Omitted of	drugs - N	on-antibi	iotics					га	tient Saf	> 12.5%	7.5-12.5%	≤ 7.5%	
	Apr 10	May 10	Jun 10	Jul 10	Aug 10	Sep 10	Oct 10	Nov 10	Dec 10	Jan 11	Feb 11	Mar 11	YTD
Antibiotics	6.3%	6.2%											6.2%
Non-ABX	14.4%	14.6%											14.6%
The percent March. The slightly from place on 2 mouth (NBM be provided are NBM. P non-stock of practice on roll out of P theatre are use of the review PICS	e percentage 14.4% to 6 May. Thi M) not bein I to nursing ossible imp frugs and t wards for ICS to Thea not record patient leave	ge of omit 14.6%. The is identified g given dru staff about rovements the matchir the time of atres is also ed as omit ve function	tted non-a second ro d problems gs when th t which dru to PICS to ng of drug drug round b being inve ted. Staff a in PICS a	ntibiotic de ot cause au with patie ney could l gs can be allow the a rounds in ds are beir estigated so are to be e	oses howe nalysis mee ents who a be; clarifica given wher nutomatic on PICS to the ng investiga o that doses	ever rose eting took ire nil by ttion is to n patients rdering of he actual ated. The s given in to make	25% 20% 15% 10% 5% 0% 60 60 60 60 60 60 60 60 60 60 60 60 60				-	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
Readmission audit response rate Non-emergency mortality audit response rate								Patient Outcomes				80-90% 90-100%	> 90% 100%

	igeney n			ponoc ru						. 00 /0	00 100 /0	10070	
	Apr 10	May 10	Jun 10	Jul 10	Aug 10	Sep 10	Oct 10	Nov 10	Dec 10	Jan 11	Feb 11	Mar 11	YTD
Readmissions	27.5%	20.3%											24.0%
Non-Em Mortality	87.5%												87.5%
Forms sent out	7												7
Forms completed	8												8

The response rate for readmission audits for May 2010 is 20.3%. A new readmission module of Healthcare Evaluation Data (HED) tool has been developed by Informatics which shows comparative data for readmissions for the whole of England. It also allows readmissions to other hospitals to be tracked as well as patients readmitted to UHB following discharge from other hospitals. The tool identifies patients with a readmitting diagnosis that is potentially similar to the discharge diagnosis. Analysis on readmissions is particularly pertinent as the Secretary of State has announced that hospitals will not be paid for the treatment of patients readmitted within 30 days of discharge. There continues to be one outstanding response for April 2010 for the non-emergency mortality audit which has not been completed because the patient's notes are with the coroner.

